CLEC2D and acute lymphoblastic leukemia: As shown in Figure 2E, LLT1 was observed to be significantly overexpressed in CD3+ T cells of high-risk ALL (31.67%) subjects as compared to healthy (5.8%) subjects (p < 0.01) at diagnosis (day 0, 1BD), which dropped down post-induction chemotherapy (day 29, 2BD) treatment to comparable levels of expression (12.17%) with healthy subjects (Figure 2F).